New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export NVO’s income statement to Excel — free account
Novo Nordisk A/S
NVOHealthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +3.87%
- EPS
- −17.1%
- Free cash flow
- −14.8%
- Total debt
- +30.7%
Quarter to September 2026, against a year earlier
38.51
0.38
−0.98%
Follow NVO
Alert me
Where the cash went Twelve months to Sep 30, 2026
Free cash flow of $10.9B covered $9.3B of dividends and buybacks. Cash rose by $1.8B. What is a cash flow statement?
- Free cash flow
- $10.9B 56.8% of operating cash flow
- Returned to shareholders
- $9.3B 84.9% of free cash flow
- Debt, net
- $4.7B borrowed
- Change in cash
- +$1.8B over the period
| Operating cash flow | 19.2 |
|---|---|
| Capital expenditures | −8.3 |
| Free cash flow | 10.9 |
| Into investments, net | −0.3 |
| Dividends | −7.7 |
| Buybacks, net | −1.5 |
| Debt raised, net | +4.7 |
| Other | −4.3 |
| Change in cash | 1.8 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $18.0B | $18.3B | $20.4B | $19.2B |
| Capex | −$9.1B | −$9.0B | −$8.6B | −$8.3B |
| Free cash flow | $8.9B | $9.4B | $11.9B | $10.9B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
16,966.52 | 17,882.69 | 19,015.84 | 15,508.51 |
+8 more TTM periods Free account |
Depreciation & Amortization |
5,101.35 | 4,163.94 | 3,341.40 | 3,328.08 | |
Non Cash Items (Other) |
1,734.93 | 4,154.21 | 4,162.02 | 3,961.68 | |
Accounts Receivable Change |
— | — | — | (4,343.01) | |
Change in inventories |
— | — | — | (4,391.72) | |
Accounts Payable Change |
— | — | — | 3,272.05 | |
Change in other assets and liabilities |
895.70 | (169.63) | (1,732.77) | 1,153.21 | |
Other operating activities |
(4,725.23) | (4,839.88) | (5,686.14) | (5,152.90) | |
Operating Cash Flow |
19,206.72 | 20,424.78 | 18,333.80 | 18,032.04 | |
Capital expenditures |
(8,304.06) | (8,565.99) | (8,982.65) | (9,105.20) | |
Change in intangibles (net) |
(4,024.16) | (4,248.26) | (4,487.68) | (4,537.91) | |
Net Aquisitions |
— | — | (11,658.34) | (11,761.62) | |
Short Term Investments Change (Net) |
— | — | — | 1,536.10 | |
Long-Term Investments Change (Net) |
5.22 | 4.17 | (10.01) | (29.52) | |
Other investing activities |
(397.38) | 53.22 | (341.23) | — | |
Investing cash flow |
(12,387.44) | (12,610.90) | (12,877.06) | (11,984.52) | |
Repayment/Issuance of Debt (Net) |
4,726.72 | 5,550.97 | 3,891.95 | 3,746.09 | |
Equity Repurchase (Common, Net) |
(1,533.09) | (916.91) | (390.14) | (210.14) | |
Dividends Paid (Total) |
(7,722.82) | (7,992.75) | (11,246.04) | (7,836.92) | |
Other financial activities |
421.55 | 1,268.97 | 3,174.84 | — | |
Financing cash flow |
(5,030.14) | (3,788.00) | (7,800.12) | (4,300.97) | |
Exchange Rate Adjustment |
(1.64) | (8.64) | (141.15) | (110.07) | |
Change in Cash |
1,787.50 | 4,017.25 | (2,484.52) | 1,636.48 | |
Beginning Cash |
3,994.05 | 4,106.84 | 4,305.51 | 2,370.17 | |
Ending Cash |
5,781.55 | 8,124.09 | 1,820.99 | 4,006.65 | |
Stock Based Compensation |
— | — | — | 915.61 | |
Dividends Paid (Common) |
(7,722.82) | (7,992.75) | (11,246.04) | (7,836.92) | |
Assets Liabilities Change (Total) |
129.16 | (936.17) | (2,499.31) | 386.68 | |
Investments Change (Net) |
(309.18) | (1.87) | 393.35 | 1,506.58 | |
Issuance/Purchase of Shares |
(1,533.09) | (916.91) | (390.14) | (210.14) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026